Walmart’s U.S. same-store sales grew only 2.6% last quarter, its slowest pace in more than six years, even as total revenue rose.
Story Highlights
- U.S. comparable sales rose 2.6% in Q2, the weakest growth in over six years.
- Total revenue increased about 5% as online sales stayed strong.
- Walmart cited pharmacy pricing rules as a key drag on growth.
- Excluding the pharmacy hit, core U.S. comps were stronger, near 3.4%.
What Walmart Reported And Why It Matters
Walmart said U.S. comparable sales rose 2.6% in the quarter ended July 31, 2026. That was the slowest growth for this measure in more than six years and missed some Wall Street estimates, which helped push the stock lower after the report. Comparable sales track gains at stores and online for locations open at least a year. Investors watch this metric to judge steady demand from existing customers without the noise of new store openings.
At the same time, Walmart’s overall business kept growing. The company reported revenue growth of about 5%, with management highlighting strong top-line results and solid traffic trends. Digital sales stayed a bright spot, with global e-commerce up sharply from a year ago. Those numbers show the slowdown was not across every channel. The company pointed to steady transactions and online demand as signs that many shoppers still chose Walmart for price and convenience.
Pharmacy Pricing Rules Hit Health And Wellness Sales
Company leaders tied part of the slowdown to new pharmacy pricing rules that lowered prices for certain drugs. That pushed down reported sales in health and wellness, a large category for Walmart. Reporters and the company said this “Maximum Fair Price” effect weighed on comparable sales. Excluding that pharmacy drag, core U.S. comparable sales would have been meaningfully higher than the headline 2.6%, closer to 3.4% according to coverage of the release.
These policy shifts reflect a bigger debate over how the government sets healthcare prices and who bears the cost. When rules cap prices, families may pay less at the counter, but retailers can see lower sales growth. That trade-off can confuse the market if investors focus only on a single number. Walmart’s explanation separates consumer demand from a regulatory price reset, but it did not quantify how much consumer caution versus pharmacy pricing each contributed.
What The Slowdown Says About Shoppers And The Economy
Analysts often treat Walmart as a window into household budgets. A softer comparable-sales figure can signal that families are watching every dollar. Several reports said shoppers pulled back on some items, favoring value and essentials over discretionary goods. That fits a wider trend: people have faced higher living costs for years, from food to energy. In that setting, price caps in one category can help wallets while still muddying retail metrics used to judge the whole economy.
$WMT Walmart posted its worst single-day drop in more than four years.
Q2 US comparable sales grew 2.6% versus the 3.5% FactSet consensus. Q3 fiscal 2027 EPS guidance and full-year EPS guidance both came in below Wall Street expectations, offsetting Walmart's strong revenue…
— Finance Spot (@financespotnews) August 21, 2026
For both the right and the left, this report touches a shared worry: the system seems to work for large interests while regular people squeeze every paycheck. Consumers want lower drug prices and fair bills. Investors want clean signals from company data. Policy changes can deliver relief but also distort key measures. Walmart’s quarter shows how headline numbers can miss the full picture, even as online growth and steady traffic point to a business adapting in a tough environment.
How To Read The Next Few Quarters
The next test is whether the comp slowdown proves temporary. Watch three items: traffic, average ticket size, and e-commerce. If traffic stays firm and digital growth holds, demand is likely resilient. If average ticket improves without a jump in prices, that could show healthier baskets. Finally, watch management guidance for any change in how they frame the pharmacy headwind. Clearer breakouts can help investors separate policy effects from true consumer weakness.
Sources:
feedpress.me, wsj.com, ttnews.com, nypost.com, investing.com, finance.yahoo.com, reuters.com, stock.walmart.com
